ArticleScientific reports2026
Uptake in thyroid Tripterygium glycosides, enhances radioiodine cancer by promoting the expression and function of NIS.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The dysfunction of the sodium-iodide symporter (NIS) is a key contributor to radioiodine (RAI) treatment failure in advanced thyroid cancer. This dysfunction exists on a spectrum, ranging from intrinsically suppressed NIS expression-often driven by constitutive oncogenic signaling-to its complete loss in dedifferentiated disease. While MAPK pathway inhibitors represent a promising redifferentiation strategy, their clinical utility is constrained by variable efficacy and toxicity. This study aimed to investigate the potential of Tripterygium Glycosides (TG), a natural compound with known MAPK-inhibitory activity, to reactivate NIS function in preclinical models characterized by intrinsically low NIS expression, representing an early stage in the continuum of RAI resistance. This study utilized thyroid cancer cell lines with intrinsically low NIS expression. In vitroassays evaluated the effects of TG on iodide uptake, NIS expression and membrane localization, its interaction with the scaffold protein LARG, and the role of the ERK1/2 signaling pathway. In thyroid cancer mouse xenograft model, the effects of TG alone or in combination with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.